Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Gastric Adenocarcinoma 2Solid Tumor 1Small Cell Lung Carcinoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1NSCLC 1Mucosal Melanoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Diseases 1Drug-Related Side Effects and Adverse Reactions 1Digestive System Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

camrelizumab 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Esophageal Diseases × camrelizumab × Clear all
NCT05624099 2023-10-19

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Fujian Cancer Hospital

Phase 2 Recruiting
75 enrolled
Gastrointestinal

Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡